CatalYm

Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.

Total raised

€100M

€100,000,000

Funding rounds

Investors

distinct backers

Active since

2020-11

latest 2022-11

Funding by year

EUR raised per year

High confidence

Raise-next likelihood37

base rate 50% for Series C

Exit likelihood20

base rate 12% (2+ rounds)

Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.

2 rounds

Date	Stage	Amount	Investors
2022-11-23	Series C	€50M	Bayern Kapital,BioGeneration Ventures,Brandon Capital,Coparion,Forbion,Jeito Capital+2 more	View deal →
2020-11-10	Seed	€50M	—	View deal →

same sector or country